Shares of AbbVie Inc. ABBV rallied 1.34% to $185.72 Tuesday, on what proved to be an all-around positive trading session for ...

There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement after four years in the role. He will be replaced as head of AbbVie ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

INBRIJA, a dopamine replacement therapy for off periods in Parkinson's disease, holds significant market potential due to its ability to provide rapid relief from motor symptoms. With the increasing ...

At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Development of the Sunrise Battery Materials Complex (Sunrise Project) in New South Wales utilising the Consolidated Entity's Clean-iX resin technology for extraction and purification of a range ...

The treatment delayed progression by more than three months, trial results showed. Future of Healthcategory Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial 12:08 PM UTC ...